Core Viewpoint - Jiangsu Longda Superalloy Co., Ltd. is convening its second extraordinary general meeting of shareholders in 2025 to discuss key proposals, including the use of excess raised funds for operational liquidity and loan repayment, the registration of targeted debt financing tools, and a related leasing agreement to enhance employee accommodation [1][12][15]. Group 1: Use of Excess Funds - The company plans to use part of the excess raised funds, amounting to 80 million RMB, to permanently supplement working capital and repay bank loans, which constitutes 6.66% of the total excess funds of 1.2 billion RMB [8][9]. - The total raised funds from the initial public offering amounted to approximately 2.4 billion RMB, with a net amount of 2.2 billion RMB after deducting issuance costs [5][9]. - The company commits that the cumulative use of excess funds for working capital and loan repayment will not exceed 30% of the total excess funds within any 12-month period [8][9]. Group 2: Registration of Debt Financing Tools - The company intends to apply for the registration of targeted debt financing tools with a total amount not exceeding 1 billion RMB, which will be used for operational activities, including project construction and R&D [12][14]. - The proposed debt financing tools will have a term of up to 5 years, with interest rates determined based on the company's credit rating and market conditions [12][14]. - The issuance of these financing tools is subject to approval from the interbank market association and will enhance the company's financial structure and liquidity management [12][15]. Group 3: Leasing Agreement - The company plans to sign a leasing agreement with Wuxi Yuyuan Industrial Group for a property of 5,643.52 square meters to improve employee accommodation, with a total rental cost of approximately 9.83 million RMB over five years [15][20]. - This leasing transaction is classified as a related party transaction due to common control, but it does not constitute a major asset restructuring [16][22]. - The rental price is based on a real estate rental consulting report and is deemed fair and reasonable, ensuring no harm to the interests of the company and its shareholders [19][22].

Core Viewpoint - The chairman and general manager of Maiwei Biopharma, Liu Datao, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading, which raises concerns about management stability and internal control effectiveness during a critical period for the company's H-share listing [1][2]. Company Overview - Maiwei Biopharma is an innovative biopharmaceutical company with a full industry chain layout, focusing on the research, production, and sales of innovative drugs and biosimilars, including antibodies, ADC drugs, and recombinant proteins [1]. - The company has launched three products, which are gradually increasing in sales volume, but has not achieved profitability since its establishment in 2017, accumulating losses of nearly 6 billion yuan [1][7]. Financial Performance - The company reported revenues of 27.73 million yuan in 2022, 128 million yuan in 2023, and 200 million yuan in 2024, with year-on-year growth rates of 70.88%, 361.03%, and 56.28% respectively [6]. - However, in the first quarter of 2024, revenue decreased to 45 million yuan, a year-on-year decline of 33.70%, with a net loss of 292 million yuan, down 41.85% year-on-year [6][7]. - Cumulative losses since establishment exceed 6 billion yuan, with net losses of 955 million yuan, 1.05 billion yuan, and 1.04 billion yuan for the years 2022, 2023, and 2024 respectively [7]. Debt and Financing - The company's debt ratio increased from 24.00% in 2022 to 63.61% in 2024, with total liabilities reaching 2.72 billion yuan, a year-on-year increase of 44.53% [8]. - To meet funding needs and enhance internationalization, the company submitted a listing application to the Hong Kong Stock Exchange in January 2024 and is also seeking to issue up to 500 million yuan in targeted debt financing tools [8]. Management and Governance - Liu Datao, the chairman, holds 3.78% of the company's shares and has a background in molecular biology and pharmaceutical chemistry, having co-founded Maiwei Biopharma in 2017 [3][4]. - The actual controllers of the company are Tang Chunshan and Chen Shanna, holding 42.38% of the voting rights [4].